STOCK TITAN

Accendra Health faces NYSE delisting, trades on OTCQB

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Accendra Health (ACH) said the New York Stock Exchange suspended trading in its common stock on November 16, 2026, and began proceedings to delist it because of abnormally low selling price levels. The company has a right to seek review by an NYSE committee but does not intend to appeal. The NYSE said it would apply to the SEC for delisting pending completion of applicable procedures.

ACH common stock began trading on the OTCQB market under ticker ACCH on November 17, 2026. The company said the transition will not affect its business operations or SEC reporting obligations and will not conflict with or cause an event of default under its material debt or other agreements.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 1 point

How the balance works

Positive

  • None.

Negative

  • Major pointNYSE trading suspension and delisting proceedings began November 16, 2026.
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities
The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
NYSE suspension and delisting proceedings November 16, 2026 Trading was suspended and proceedings to delist the common stock began.
OTCQB trading began November 17, 2026 Common stock began trading under ticker ACCH.
delisting proceedings regulatory
"commence proceedings to delist the Company’s common stock"
Delisting proceedings are the formal steps taken to remove a company’s shares from a stock exchange, either because the company chose to leave or failed to meet rules like minimum share price, reporting or solvency requirements. For investors this matters because removal usually cuts trading access and liquidity, can sharply lower the share price, and makes it harder to buy, sell or get transparent information — similar to a product being pulled off supermarket shelves.
Section 802.01D regulatory
"pursuant to Section 802.01D of the NYSE Listed Company Manual"
OTCQB market technical
"began trading on the OTCQB market under the ticker symbol “ACCH”"
The OTCQB Market is a regulated tier of the over‑the‑counter (OTC) trading system where smaller or early‑stage stocks trade with modest reporting and quality standards. Think of it as a neighborhood market that sits between an informal garage sale and a big supermarket: it offers more information and oversight than the lowest OTC tier, but less liquidity and scrutiny than major exchanges. Investors care because it signals a middle level of transparency and risk, affecting how easy shares are to buy, sell and evaluate.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why was ACH suspended from NYSE trading?

The NYSE suspended trading in ACH common stock and began delisting proceedings based on abnormally low selling price levels, under Section 802.01D of the NYSE Listed Company Manual. ACH does not intend to appeal, and the NYSE’s application to delist is subject to applicable procedures.

Where does ACH stock trade after its NYSE suspension?

ACH common stock began trading on the OTCQB market under ticker ACCH on November 17, 2026. The company said the transition will not affect its business operations or SEC reporting obligations and will not conflict with or cause an event of default under its material debt or other agreements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0000075252false00000752522026-11-162026-11-16

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 16, 2026

Accendra Health, Inc.

(Exact name of registrant as specified in its charter)

​

​

​

​

​

​

Virginia

001-09810

54-1701843

(State or other jurisdiction of

(Commission

(I.R.S. Employer

incorporation or organization)

File Number)

Identification No.)

​

​

​

4435 Waterfront Drive, Suite 300,

Glen Allen, Virginia

​

23060

(Address of principal executive

​

​

offices)

​

(Zip Code)

​

​

​

​

Registrant’s telephone number, including area code (804) 277-4304

Securities registered pursuant to Section 12(b) of the Act:

​

​

​

​

​

​

Title of each class

  ​ ​ ​

Trading Symbol(s)

  ​ ​ ​

Name of each exchange on which registered

Common Stock, $2 par value per share

​

ACH

​

New York Stock Exchange

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.below):

​

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

​

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

​

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

​

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company         ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.          ◻

​

​

​

Item 3.01Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On November 16, 2026, Accendra Health, Inc. (the “Company”) received notice (the “Notice”) from the New York Stock Exchange (“NYSE”) Regulation that it has suspended trading of the Company’s common stock and determined to commence proceedings to delist the Company’s common stock from the NYSE. The NYSE Regulation determined that the Company’s common stock is no longer suitable for listing based on abnormally low selling price levels, pursuant to Section 802.01D of the NYSE Listed Company Manual.

​

The Company has a right to a review of this determination by a Committee of the Board of Directors of the Exchange. The Notice states that it will apply to the U.S. Securities and Exchange Commission to delist the Company’s common stock pending completion of applicable procedures, including any appeal by the Company of its determination. The Company does not intend to appeal the NYSE’s determination. 

​

The Company’s common stock began trading on the OTCQB market under the ticker symbol “ACCH” on November 17, 2026.

​

Item 7.01.Regulation FD Disclosure.

On November 17, 2026, the Company issued a press release regarding the delisting determination. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

​

The information in Exhibit 99.1 is being furnished pursuant to Item 7.01 of Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

​

Item 9.01.

Financial Statements and Exhibits.

​

(d) Exhibits.

The following materials are filed as exhibits to this Current Report on Form 8-K.

 

Exhibit Number 

 

Description

99.1

​

Press Release of the Company, dated November 17, 2026 (furnished pursuant to Item 7.01).

104

 

Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document).

​

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

​

​

​

​

​

​

​
ACCENDRA HEALTH, INC.

​

​

​

November 17, 2026

​

/s/ Jonathan A. Leon

​

​

 ​

Jonathan A. Leon

​

​

​

Executive Vice President and Chief Financial Officer

​

Exhibit 99.1

Accendra Health Receives Delisting Notice From the New York Stock Exchange

​

Trading Will Continue on the Over-the-Counter Market Under Ticker Symbol “ACCH”

​

​

RICHMOND, Va., November 17, 2026 -- Accendra Health, Inc. (NYSE: ACH) (the “Company”) today announced that it received notification from the New York Stock Exchange (“NYSE”) on November 16, 2026, informing it that trading of the Company’s common stock on the NYSE was suspended, effective immediately, and that the NYSE has determined to commence proceedings to delist the Company’s common stock. The NYSE reached its decision to delist the Company’s common stock pursuant to Rule 802.01D of the NYSE Listed Company Manual, based on abnormally low selling price levels.

​

The Company’s common stock began trading on the OTCQB market under the ticker symbol “ACCH” on November 17, 2026. This transition to the over-the-counter market will not affect the Company’s business operations or its U.S. Securities and Exchange Commission reporting obligations, and it does not conflict with or cause an event of default under any of the Company’s material debt or other agreements.

​

“We are focused on taking the necessary steps and implementing decisive measures to support our turnaround and best position the Company for long-term growth and success,” said Kenny Gardner-Smith, President & Chief Executive Officer. “We are continuing to provide innovative solutions to our patients and customers, and we remain committed to being a trusted partner across the clinical conditions we serve.”  

​

Safe Harbor

This release is intended to be disclosure through methods reasonably designed to provide broad, non-exclusionary distribution to the public in compliance with the SEC’s Fair Disclosure Regulation. This release contains certain “forward-looking” statements made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the statements in this release regarding our future prospects and performance, including our expectations with respect to our financial performance, our 2026 financial results, our expectations regarding the performance of our business following the completion of the sale of the Products & Healthcare Services business, our ability to timely and effectively execute our value creation plan, including cost saving initiatives, future indebtedness and growth, industry trends, our ability to cure noncompliance with the New York Stock Exchange listing standards, as well as statements related to our expectations regarding the performance of our business, including our ability to address macro and market conditions. Forward-looking statements involve known and unknown risks and uncertainties that may cause our actual results in future periods to differ materially from those projected or contemplated in the forward-looking statements. Investors should refer to the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 20, 2026, including the section captioned “Item 1A. Risk Factors,” as applicable, and subsequent quarterly reports on Form 10-Q and current reports on Form 8-K led with or furnished to the SEC, for a discussion of certain known risk factors that could cause the Company’s actual results to differ materially from its current estimates. These lings are available at www.accendrahealth.com. Given these risks and uncertainties, the Company can give no assurance that any forward-looking statements will, in fact, transpire and, therefore, cautions investors not to place undue reliance on them. The Company specifically disclaims any obligation to update or revise any forward looking statements, whether as a result of new information, future developments or otherwise.

​

About Accendra Health

Accendra Health, Inc. (NYSE: ACH) is a leading nationwide provider of products, technology and services that support health beyond the hospital for millions of people each year. We connect patients, providers, and insurers, delivering innovative solutions that help promote better health outcomes and improve quality of life for people living with chronic, complex health conditions. Backed by the industry-leading expertise of our Apria and Byram brands, Accendra Health is reimagining the future of home-based care. To learn more about our broad portfolio of essentials for diabetes, sleep health, wound care, respiratory care, urology and ostomy, visit www.accendrahealth.com.

1


​

ACH-CORP

​

ACH-IR

​

Contacts

Investors
Will Parrish
Vice President, Corporate Development & Investor Relations
Investor.Relations@accendra.com

​

Media
Darla Turner
media@accendra.com

2


Filing Exhibits & Attachments

5 documents

Keep reading